Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Investors Presentation of the Company. The presentation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care, a Mumbai-based oral care and personal care manufacturer, filed its investors presentation under SEBI Regulation 30. For FY24-25, total income grew 22.4% YoY to ₹1,788.92 lakhs, but PAT slipped 3.62% to ₹39.14 lakhs and Q4 FY25 turned to a loss of ₹9.93 lakhs due to USFDA-related facility upgrades halting production. Management has given FY26 revenue guidance of ₹35–40 crore with 10% PAT margin, and presented three-year projections showing revenue scaling to ₹100.97 crore by FY28 with EBITDA margins expanding from 13% to 18.3%. The company is raising ₹8 crore via a rights issue at ₹25 per share to fund expansion. Key order wins include a ₹0.74 crore oral care export order and a ₹0.48 crore skincare order, with three US export shipments already dispatched and 4–5 monthly targeted. Russian export discussions are also underway.
The presentation gives investors visibility on an aggressive growth roadmap with margin expansion projected from low double-digits to ~18% EBITDA by FY28, supported by US FDA approval and export order wins. However, near-term execution risks remain given the Q4 FY25 loss, and the ₹8 crore rights issue signals equity dilution to fund the expansion.